MétaCan
Menu
Back to cohort
Record W3130529097 · doi:10.1016/j.jhepr.2021.100260

Assessing the impact of COVID-19 on liver cancer management (CERO-19)

2021· article· en· W3130529097 on OpenAlex
Sergio Muñoz, Víctor Sapena, Alejandro Forner, Jean‐Charles Nault, Gonzalo Sapisochín, Lorenza Rimassa, Bruno Sangro, Jordi Bruix, Marco Sanduzzi‐Zamparelli, Wacław Hołówko, Mohamed El‐Kassas, Tudor Mocan, Mohamed Bouattour, Philippe Merle, Frederik J.H. Hoogwater, Saleh A. Alqahtani, Helen L. Reeves, David J. Pinato, Emmanouil Giorgakis, Tim Meyer, Gerda Elisabeth Villadsen, Henning Wege, Massimiliano Salati, Beatriz Mínguez, Giovan Giuseppe Di Costanzo, Christoph Roderburg, Frank Tacke, Marı́a Varela, Peter R. Galle, Mário Reis Álvares‐da‐Silva, Jörg Trojan, John Bridgewater, Giuseppe Cabibbo, Christian Toso, Anja Lachenmayer, Andrea Casadei‐Gardini, Hidenori Toyoda, Tom Lüdde, Rosanna Villani, Ana María Matilla Peña, Cássia Regina Guedes Leal, Monica Ronzoni, M. García Delgado, Christie Perelló, Sonia Pascual, José Luis Lledó, Josepmaria Argemí, Bristi Basu, Leonardo Gomes da Fonseca, Juan Acevedo, Alexander Siebenhüner, Chiara Braconi, Brandon M. Meyers, Alessandro Granito, Carlos Rodríguez de Lope, Lorraine Blaise, Manuel Romero‐Gómez, Federico Piñero, Dhanny Gomez, Vivianne Mello, Rogério Camargo Pinheiro Alves, Alex Vianey Callado França, Fernanda Branco, Giovanni Brandi, Gustavo Alessandro de Sousa Pereira, S. Coll, Maria Guarino, Carlos Benítez, María Margarita Anders, Juan Carlos Bandi, Mercedes Vergara, Mariona Calvo, Markus Peck‐Radosavljevic, Ignacio García‐Juárez, Vincenzo Cardinale, Mar Lozano, Martina Gambato, S. Okolicsanyi, Dalia Morales‐Arráez, Alessandra Elvevi, Alberto E. Muñoz, Alberto Luè, Massimo Iavarone, María Reig

Why this work is in the frame

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

affAt least one author lists a Canadian institution in the pinned OpenAlex snapshot.

Bibliographic record

VenueJHEP Reports · 2021
Typearticle
Languageen
FieldMedicine
TopicCOVID-19 and healthcare impacts
Canadian institutionsJuravinski Cancer CentreToronto General HospitalMcMaster UniversityUniversity of TorontoUniversity Health Network
FundersUCLH Biomedical Research CentreSanofi GenzymeEMD SeronoImperial Experimental Cancer Medicine CentreCancer Treatment and Research TrustCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y DigestivasIpsenUniversity College London Hospitals NHS Foundation TrustBasilea PharmaceuticaEisaiDaiichi-SankyoNational Institute for Health and Care ResearchIncyteBTGAbbVieWorldwide Cancer ResearchSocietat Catalana de DigestologiaAssociation for International Cancer ResearchSirtex MedicalWellcome TrustCancer Research UKEuropean Cooperation in Science and TechnologyBoston Scientific CorporationAlbert Einstein Cancer CenterExelixisMeso Scale DiagnosticsBayerGilead SciencesRocheCelgeneNovartisNIHR Imperial Biomedical Research CentreMerckImperial College LondonGlaxoSmithKlineAgència de Gestió d'Ajuts Universitaris i de RecercaAstraZenecaEli Lilly and CompanyBristol-Myers SquibbInstituto de Salud Carlos IIIAmgen
KeywordsCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MedicineLiver cancerVirologyCancerInternal medicineInfectious disease (medical specialty)

Abstract

fetched live from OpenAlex

•The coronavirus disease 2019 (COVID-19) pandemic had a worldwide impact on liver cancer management.•Screening programmes were modified or cancelled in 80.9% of participating centres.•All but systemic treatments were cancelled or delayed in almost all centres.•Phone call visits were the tools for patient follow-up during the first wave.•The role of the nurses was key to maintaining clinical practice and clinical trials. Background & AimsThe coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic.MethodsAn international survey evaluated the impact of the COVID-19 pandemic on clinical practice and clinical trials from March 2020 to June 2020, as the first phase of a multicentre, international, and observational project. The focus was on patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first COVID-19 pandemic wave.ResultsNinety-one centres expressed interest to participate and 76 were included in the analysis, from Europe, South America, North America, Asia, and Africa (73.7%, 17.1%, 5.3%, 2.6%, and 1.3% per continent, respectively). Eighty-seven percent of the centres modified their clinical practice: 40.8% the diagnostic procedures, 80.9% the screening programme, 50% cancelled curative and/or palliative treatments for LC, and 41.7% modified the liver transplantation programme. Forty-five out of 69 (65.2%) centres in which clinical trials were running modified their treatments in that setting, but 58.1% were able to recruit new patients. The phone call service was modified in 51.4% of centres which had this service before the COVID-19 pandemic (n = 19/37).ConclusionsThe first wave of the COVID-19 pandemic had a tremendous impact on the routine care of patients with liver cancer. Modifications in screening, diagnostic, and treatment algorithms may have significantly impaired the outcome of patients. Ongoing data collection and future analyses will report the benefits and disadvantages of the strategies implemented, aiding future decision-making.Lay summaryThe coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems globally. Herein, we assessed the impact of the first wave pandemic on patients with liver cancer and found that routine care for these patients has been majorly disrupted, which could have a significant impact on outcomes. The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic. An international survey evaluated the impact of the COVID-19 pandemic on clinical practice and clinical trials from March 2020 to June 2020, as the first phase of a multicentre, international, and observational project. The focus was on patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first COVID-19 pandemic wave. Ninety-one centres expressed interest to participate and 76 were included in the analysis, from Europe, South America, North America, Asia, and Africa (73.7%, 17.1%, 5.3%, 2.6%, and 1.3% per continent, respectively). Eighty-seven percent of the centres modified their clinical practice: 40.8% the diagnostic procedures, 80.9% the screening programme, 50% cancelled curative and/or palliative treatments for LC, and 41.7% modified the liver transplantation programme. Forty-five out of 69 (65.2%) centres in which clinical trials were running modified their treatments in that setting, but 58.1% were able to recruit new patients. The phone call service was modified in 51.4% of centres which had this service before the COVID-19 pandemic (n = 19/37). The first wave of the COVID-19 pandemic had a tremendous impact on the routine care of patients with liver cancer. Modifications in screening, diagnostic, and treatment algorithms may have significantly impaired the outcome of patients. Ongoing data collection and future analyses will report the benefits and disadvantages of the strategies implemented, aiding future decision-making.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.256
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.150
GPT teacher head0.507
Teacher spread0.358 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it